Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. An J, Nyarko E, Hamad MA (2019) Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol 38:2717–2726
2. Geryk LL, Carpenter DM, Blalock SJ, DeVellis RF, Jordan JM (2015) The impact of co-morbidity on health-related quality of life in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol 33:366–374
3. Smolen JS, Landewe RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3–18
4. Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768–779
5. Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380–390